Novel CRISPR-Cas based therapeutic strategy to decrease toxic RNA and protein products generated from nucleotide repeats
Generated by a Claude Opus 4.7 agent (max thinking effort, 1M-context). Sources cited inline. Full disclosure at /methodology/jhtv-deep-dive.
Indication
Neurological and neuromuscular disorders caused by nucleotide repeat expansions
Modality
Gene Therapy
Mechanism
CRISPR-Cas gene editing
Target
—
rNPV Envelope
Low
-$45.0M
costs +25% · peak −25%
Base
$6.5M
cumulative PoS 7.3%
High
$58.0M
costs −25% · peak +25%
Repeat-expansion CRISPR is costed as high-complexity gene therapy with rare-disease trial sizes. Avidity and Wave anchor genetically selected repeat-expansion clinical development; CASGEVY anchors gene-editing regulatory and CMC burden.
Composite score breakdown
Locked rubric — 40/30/30 weights
Clinical relevance · 40%
0.80
Modality fit · 30%
0.74
Whitespace · 30%
0.50
Composite 0.692 — composite-score rank #4 of 10 top-tier inventions in the jhtv-portfolio@2026-Q2 cohort. The page header uses rNPV rank (#3) to match the index ordering.
Comparators
Real programs anchoring the engine inputs
AOC 1001 / delpacibart etedesiran (Avidity Biosciences) — DM1 RNA therapy
Clinical repeat-expansion neuromuscular comparator for genetically defined DM1.
Criteria 2 and 3: same repeat-expansion disease class and orphan neuromuscular regulatory path.
WVE-003 (Wave Life Sciences) — allele-selective HD oligonucleotide
Genetically stratified repeat-expansion CNS program anchoring biomarker selection risk.
Criteria 2 and 3: same repeat-expansion neurogenetic disease family with allele/biomarker-defined enrollment.
CASGEVY (Vertex/CRISPR Therapeutics) — exagamglogene autotemcel
Launched CRISPR therapeutic benchmark for editing risk, pricing, and regulatory scrutiny.
Criteria 3 and 4: same gene-editing modality and serious genetically defined disease pathway.
Stage profile
Asset-specific cost, duration, and PoS by stage
| Stage | Cost | Duration | PoS | Citations |
|---|---|---|---|---|
| Preclinical | $25.0M | 24 mo | 52.0% | [0] [1] [4] |
| Phase I | $90.0M | 18 mo | 55.0% | [0] [1] [2] [5] |
| Phase II | $200.0M | 30 mo | 47.0% | [0] [1] [5] |
| Phase III | $280.0M | 36 mo | 60.0% | [2] [4] [5] |
| NDA/BLA Review | $18.0M | 12 mo | 90.0% | [2] [5] |
Multiplier handling: Eligible multipliers (genetic_validation_2.6x, biomarker_1.7x, orphan_1.4x, gene_therapy_1.41x, fast_track_or_rmat, pediatric_voucher) are already reflected in Day-1 comparator-calibrated PoS. Re-applying them via log-odds stacking would double-count, so per-stage PoS is taken as final. See methodology for the rule.
Peak revenue and discount rate
$1.30B peak · WACC 14.0%
Peak revenue. Peak revenue is a franchise estimate across at least DM1, Huntington disease, and another repeat-expansion disorder. It is modeled below CFTR-scale chronic therapy but above single ultra-rare programs because the platform can reuse editing logic across related diseases.
WACC. Durable editing upside is large, but CNS/neuromuscular delivery and off-target risk justify elevated discounting.
Sensitivity (tornado)
Top drivers of rNPV variance
Drivers ranked by absolute rNPV swing. The vertical tick inside each bar marks the base rNPV ($6.5M); each bar spans the rNPV range produced by flexing one input between its low and high values. Gold = the input pushes rNPV up when increased; red = the input pushes rNPV down when increased.
Monte Carlo distribution
1,000 trials · rpNPV mode
This is a bimodal distribution by construction, not a Gaussian. Most paths terminate in clinical failure (red cluster — accumulated cost only); a minority succeed and capture full peak revenue (green tail). Bar heights are square-root-scaled so the success tail stays visible alongside the much taller failure cluster; exact counts are preserved in the percentiles below. Gold line = median (P50). Navy dashed = base rNPV (mean) — the probability-weighted expected value, which can sit above the median when the upper tail is strong enough to outweigh the failure cluster (and close to the median when it isn’t).
P5
-$269.7M
P25
-$111.3M
P50 (median)
-$38.8M
P75
-$15.4M
P95
$1.10B
Prob ≥ 0
7.9%
Evidence register
6 per-assumption citations
| Assumption | Source | Date | Confidence |
|---|---|---|---|
AOC 1001 repeat-expansion comparator comparators[0] | ClinicalTrials.gov NCT05027269: AOC 1001 in myotonic dystrophy type 1 trial_disclosure | 2021-09-01 | high |
WVE-003 repeat-expansion CNS comparator comparators[1] | ClinicalTrials.gov NCT05032196: WVE-003 in Huntington disease trial_disclosure | 2021-09-02 | high |
CASGEVY regulatory gene-editing precedent comparators[2] | FDA approves first gene therapies to treat patients with sickle cell disease regulatory | 2023-12-08 | high |
CASGEVY revenue and launch context peak_revenue_usd | Vertex Pharmaceuticals Annual Report 2024 company_filing | 2025-02-13 | high |
Gene-editing cost bounds stage_profile.phase_1.cost_usd_m | Wouters et al., Estimated R&D Investment Needed to Bring a New Medicine to Market, JAMA 2020 peer_review | 2020-03-03 | medium |
Rare biomarker PoS adjustment stage_profile.phase_2.pos | BIO/QLS/Informa Clinical Development Success Rates 2011-2020 peer_review | 2021-02-17 | medium |
Thesis
Why this asset earns its top-10 rank
The CRISPR repeat-expansion asset targets a shared disease mechanism: toxic repeat RNAs and proteins in neurological and neuromuscular disorders. It ranks in the top 10 because the patient populations are genetically defined, the unmet need is high, and the platform could extend across more than one repeat-expansion disease.
Avidity's AOC 1001 and Wave's WVE-003 anchor the repeat-expansion development context, while CASGEVY demonstrates that CRISPR-based medicines can clear regulatory review when the biology and manufacturing are controlled. The engine result is -$45.0M to $58.0M, with a base rNPV of $6.5M and cumulative PoS of 7.3%; that supports a VC-fundable view, but the high case depends on repeatable delivery across at least two or three indications rather than a single narrow launch.
The Phase I PoS reflects the in-vivo CNS/muscle CRISPR maturity bar rather than ex-vivo precedent: as of 2026 there are no pivotal-stage in-vivo CNS-CRISPR programs, with Editas's EDIT-101 (in-vivo CRISPR for LCA10) paused/deprioritized after only 3 of 14 patients showed clinically meaningful improvement and the company now seeking a partner, and Verve's VERVE-101/-102 (PCSK9 base editing) the only credible in-vivo CRISPR with positive Phase 1 data — and liver is the easiest in-vivo organ for LNP delivery. CNS and muscle delivery remain unproven at the pivotal stage.
The verdict is a platform-shaped genetic-medicine opportunity with genuine financing logic. The top-10 ranking is justified by causal genetics and whitespace, but the next diligence step is delivery and off-target evidence, not a bigger market model.
Key risks
Asset-specific, not generic biotech risks
- In vivo CRISPR delivery to affected CNS or muscle tissues may be the limiting factor.
- Repeat-expanded loci create off-target and genotoxicity concerns distinct from ex vivo editing.
- Disease heterogeneity across DM1, Huntington disease, and related disorders may limit platform reuse.
- Regulators may require long follow-up before accepting irreversible repeat-targeting edits.
- In-vivo CRISPR delivery to CNS/muscle has zero pivotal-stage approvals as of 2026 (Editas EDIT-101 deprioritized 2024; Verve VERVE-101/-102 liver-only). Phase I PoS 0.55 reflects this maturity bar; upside requires maturation of in-vivo non-liver CRISPR delivery before pivotal.